Despite advances in laparoscopic surgery combined with neoadjuvant and adjuvant
therapy, colon cancer management remains challenging in oncology. Recurrence of …

Cowpea mosaic virus (CPMV) is a potent immunogenic adjuvant and epitope display
platform for the development of vaccines against cancers and infectious diseases, including …

Contemporary immunotherapies, eg, those that target the CTLA‐4 and PD‐1/PD‐L1 axis, act
on T cells to reinstate their antitumor activity. An alternative, and possibly more powerful …

Cowpea mosaic virus (CPMV) is currently in the development pipeline for multiple
biomedical applications, including cancer immunotherapy. In particular the application of …

Our lab demonstrated that intratumoral Cowpea mosaic virus (CPMV) is a potent antitumor
immunotherapy when used as in situ vaccine. As we pave the way for human clinical …

Nanotechnology has tremendous potential to contribute to cancer immunotherapy. The 'in
situ vaccination'immunotherapy strategy directly manipulates identified tumours to overcome …

The immunosuppressive tumor microenvironment enables cancer to resist
immunotherapies. We have established that intratumoral administration of plant-derived …

Cancer immunotherapies are designed to facilitate recognition and elimination of
transformed cells by the immune system. We have established the immunotherapeutic …

Cowpea mosaic virus (CPMV) has demonstrated superior immune stimulation and efficacy
as an intratumoral immunotherapy, providing a strong argument for its clinical translation …

Peritoneal metastases (PMs) occur due to the metastasis of gynecological and
gastrointestinal cancers such as ovarian, colon, pancreatic, or gastric tumors. PM outgrowth …